We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
In the latest close session, Novavax (NVAX - Free Report) was up +1.01% at $8.01. The stock outperformed the S&P 500, which registered a daily gain of 0.29%. Elsewhere, the Dow lost 0.31%, while the tech-heavy Nasdaq added 0.89%.
The vaccine maker's stock has climbed by 2.92% in the past month, exceeding the Medical sector's gain of 0.32% and lagging the S&P 500's gain of 10.54%.
Investors will be eagerly watching for the performance of Novavax in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on May 6, 2026. The company's earnings per share (EPS) are projected to be -$0.25, reflecting a 108.53% decrease from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $60.39 million, showing a 90.94% drop compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.06 per share and a revenue of $378.8 million, signifying shifts of -102.33% and -66.28%, respectively, from the last year.
Investors should also note any recent changes to analyst estimates for Novavax. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 96.21% lower. At present, Novavax boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 146, this industry ranks in the bottom 41% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
In the latest close session, Novavax (NVAX - Free Report) was up +1.01% at $8.01. The stock outperformed the S&P 500, which registered a daily gain of 0.29%. Elsewhere, the Dow lost 0.31%, while the tech-heavy Nasdaq added 0.89%.
The vaccine maker's stock has climbed by 2.92% in the past month, exceeding the Medical sector's gain of 0.32% and lagging the S&P 500's gain of 10.54%.
Investors will be eagerly watching for the performance of Novavax in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on May 6, 2026. The company's earnings per share (EPS) are projected to be -$0.25, reflecting a 108.53% decrease from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $60.39 million, showing a 90.94% drop compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.06 per share and a revenue of $378.8 million, signifying shifts of -102.33% and -66.28%, respectively, from the last year.
Investors should also note any recent changes to analyst estimates for Novavax. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 96.21% lower. At present, Novavax boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 146, this industry ranks in the bottom 41% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.